Announcements Trials
Browse Landscape

Phase

Phase NA 45Phase 2 8Phase 3 5Phase 2/3 3Phase EARLY_PHASE1 1Phase 4 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 2Colorectal Neoplasms 2Weight Loss 1Sleep Initiation and Maintenance Disorders 1Protein Deficiency 1Prostatic Neoplasms 1Prolactinoma 1Neoplastic Cells, Circulating 1Neoplasms 1Multiple Myeloma 1Melanoma 1Malnutrition 1Kidney Neoplasms 1Iron Deficiencies 1Hemostasis 1Delirium 1Carcinoma, Renal Cell 1Anemia 1

Interventions

Dexamethasone 8Oxycodone 6Epoetin Alfa 5Propofol 4Palonosetron 4Meropenem 4Zoledronic Acid 3Vancomycin 3Sevoflurane 3Ondansetron 3Naloxone 3Everolimus 3Ciprofloxacin 3Cholecalciferol 3Ceftazidime 3Cefepime 3Calcium Dobesilate 3Bevacizumab 3Aspirin 3Aprepitant 3peginterferon alfa-2a 2edoxaban 2apixaban 2apatinib 2Vitamin B 12 2Vincristine 2Tobacco Use Cessation Devices 2Teicoplanin 2Tablets 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms × Standard of Care × Clear all
NCT03831633 2019-02-06

Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients

VIFORFRANCE

Phase 4 Unknown
426 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡